ISIS 9125

Drug Profile

ISIS 9125

Alternative Names: IP 9125

Latest Information Update: 08 Jun 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Isis Pharmaceuticals
  • Class Anti-inflammatories; Oligonucleotides
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammatory bowel diseases; Transplant rejection

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Inflammatory bowel disease in USA (Unknown route)
  • 08 Jun 2001 No-Development-Reported for Transplant rejection in USA (Unknown route)
  • 30 Dec 1998 Preclinical development for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top